
Heliyon, Journal Year: 2024, Volume and Issue: 10(19), P. e38074 - e38074
Published: Sept. 18, 2024
Language: Английский
Heliyon, Journal Year: 2024, Volume and Issue: 10(19), P. e38074 - e38074
Published: Sept. 18, 2024
Language: Английский
Journal of Molecular Structure, Journal Year: 2025, Volume and Issue: unknown, P. 141436 - 141436
Published: Jan. 1, 2025
Language: Английский
Citations
0Journal of Cellular Biochemistry, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 19, 2024
ABSTRACT This study investigates the repurposing potential of non‐nucleosidic reverse transcriptase inhibitors (NNRTIs), specifically Rilpivirine and Etravirine, as L858R/T790M tyrosine kinase for addressing acquired resistance in non‐small cell lung cancer (NSCLC). Using silico molecular docking, demonstrated a docking score −7.534 kcal/mol, comparable to established epidermal growth factor receptor (EGFR TKIs) like Osimertinib WZ4002. Molecular dynamics (MD) simulations over 200 ns revealed stability Rilpivirine–EGFR complex, with RMSD values ranging from 2.5 3.5 Å. The vitro antiproliferative assays showed that had an IC 50 value 2.3 µM against H1975 cells, while WZ4002 0.291 µM, indicating moderate efficacy. Enzymatic inhibited double mutant TK) 54.22 nM spared wild‐type EGFR TK 22.52 nM. These findings suggest Rilpivirine's therapeutic agent NSCLC mutations
Language: Английский
Citations
1Heliyon, Journal Year: 2024, Volume and Issue: 10(19), P. e38074 - e38074
Published: Sept. 18, 2024
Language: Английский
Citations
0